| Metric | Value (₹ Cr) | Q1 FY27 | Q2 FY26 |
|---|---|---|---|
| Revenue | 795.03 | 5.1% | 40.1% |
| Total Income | 800.54 | 4.7% | 39.4% |
| Expenditure | 713.25 | 5.2% | 33.6% |
| PBT | 87.29 | 0.7% | 115.6% |
| Net Profit | 65.07 | 1.0% | 117.1% |
| OPM | 13.76% | 0.08pp | 3.70pp |
| NPM | 8.13% | 0.29pp | 2.91pp |
| EPS | 2.21 | 0.5% | 116.7% |
Revenue (+40.1%) and PAT (+117.1%) both grew strongly with OPM expanding to 13.8% from 10.1%, a broad-based, margin-led beat for a pharma/API business with no sign of one-off drivers.
IOL Chemicals Reports Highest-Ever Quarterly Revenue, EBITDA & PAT
30 Oct 2026 · 30 Oct, 8:11 pm
Summary
IOL Chemicals and Pharmaceuticals Limited reported strong financial results for Q2 and H1 FY27, achieving record-high quarterly revenue, EBITDA, and PAT. Revenue from operations grew by 20.1% year-on-year to ₹795.0 Cr in Q2 FY27, driven by healthy demand and improved operational efficiencies. EBITDA saw a substantial increase of 79.6% to ₹114.9 Cr, with EBITDA margins expanding by 321 basis points. Profit After Tax more than doubled, growing 116.8% to ₹65.0 Cr, reflecting improved product mix and operating efficiencies. Management highlighted the growing contribution of the non-Ibuprofen portfolio and significant improvements in the Chemicals business as key growth drivers.
Key Highlights
- 1
IOL Chemicals and Pharmaceuticals Limited announced its Unaudited Financial Results for the quarter and half year ended 30th September 2026.
- 2
The company recorded its highest-ever quarterly revenue, EBITDA, and PAT.
- 3
Revenue from operations for Q2 FY27 was ₹795.0 Cr, a significant increase of 20.1% year-on-year.
- 4
EBITDA for Q2 FY27 surged by 79.6% to ₹114.9 Cr compared to ₹64.0 Cr in Q2 FY26.
- 5
Profit After Tax (PAT) for Q2 FY27 more than doubled, growing by 116.8% to ₹65.0 Cr.
- 6
The non-Ibuprofen portfolio in the Pharmaceuticals business registered approximately 70% year-on-year revenue growth, contributing 45% of pharmaceutical revenue.
- 7
The Chemicals business EBIT contribution increased to approximately 7% from 1% in the corresponding quarter last year.
Management Comments
Vikas Gupta
We are encouraged by our performance in Q2 FY27, supported by healthy demand across key products and improved operational efficiencies. Our diversified business model has enabled us to sustain growth momentum amid continued geopolitical uncertainties and evolving global market conditions. Better product mix and operating efficiencies also contributed to a 321-basis-point year-on-year expansion in EBITDA margin. Our Pharmaceuticals business continued to perform well, backed by healthy demand across the portfolio. A key highlight was the growing contribution of our non-Ibuprofen portfolio, which registered approximately 70% year-on-year revenue growth and accounted for 45% of pharmaceutical revenue during the quarter, compared with 38% in Q2 FY26. This underscores the progress of our diversification strategy and our efforts to build a broader pharmaceutical portfolio. The Chemicals business also recorded a significant improvement, supported by healthy demand across products. The segment's EBIT contribution increased to approximately 7% from 1% in the corresponding quarter last year, reflecting improved realisations and operating performance. Looking ahead, we are focused on leveraging our established manufacturing capabilities to move further up the value chain. Our forward integration into CDMO and formulation manufacturing is a natural extension of our process expertise, enabling us to provide a wider range of solutions to existing customers, deepen business relationships and unlock new growth opportunities. Going forward, our priorities will remain centred on portfolio diversification, operational excellence and expanding our presence in higher-value manufacturing, while continuing to strengthen our leadership in established product categories. We believe these initiatives will reinforce our competitive positioning and support sustainable long-term growth.
Informational and educational content only. Not investment advice.